Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Reexamination Certificate
2011-03-01
2011-03-01
Canella, Karen A (Department: 1643)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
C424S178100, C424S181100, C424S183100, C530S388100, C530S388850
Reexamination Certificate
active
07897139
ABSTRACT:
The present invention is directed to the diagnosis and treatment of diseases, preferably the inhibition of tumor growth and its progression to metastatic sites, through the inhibition of the production of PTHrP, its isoforms or PTHrP signalling. The present invention is also directed to methods of inhibiting the PTHrP1-173 isoform through antagonists thereof, including monoclonal antibodies and siRNA directed there against. The invention may be applicable to many disease states, including but not limited to several types of cancer (such as breast, lung, prostate, melanoma and squamous) expressing PTHrP and its isoforms, alone or in combination with other therapeutic agents.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5614396 (1997-03-01), Bradley et al.
patent: 2004/0005593 (2004-01-01), Lorens
patent: 2006/0003916 (2006-01-01), Massfelder et al.
patent: WO97/04312 (1997-02-01), None
Clark (Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, 1993, pp. 4-5).
Deftos et al (Proceed Amer Assoc Can Res, 2002, p. S286).
Goomer et al (Endocrinology, 2000, vol. 141, pp. 4613-4622).
Nishigaki et al (Clinical Cancer Research, 1999, vol. 1475-1481).
Wong et al (Clinical Cancer Research, 2003, vol. 9, pp. 5842-5852).
Mach et al (Cancer Research, 1983, vol. 43, pp. 5593-5600).
Francis et al (British journal of Cancer, 2002, vol. 87, pp. 600-607).
Maurer and Callahan, Methods in Enzymology, 1980, vol. 70A, pp. 49-70).
Abstract of Wheeler (Salud p'ublica de M'exico, (Jul.-Aug. 1997) 39 (4) 283-7).
Efferson et al (Anticancer research, 2005, vol. 25, pp. 715-724).
Bachman et al (Journal of Immunology, 2005, vol. 175, pp. 4677-4685).
Abstract of Ramel et al, Environmental Science Research, 1984, vol. 31, pp. 97-112).
Bagi C. Skeletal complications of malignancy—Third North American Symposium. IDrugs (2002) 5:553-556.
Birch MA et al. Parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor expression and mitogenic responses in human breast cancer cell lines. Br J Cancer (1995) 72:90-5.
Bouizar Z et al. Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases. Cancer Res (1993) 53:5076-8.
Bundred et al. Parathyroid hormone related protien and hypercalcemia in breast cancer. Br Med J (1991) 303:1506-1509.
Budayr AA et al. Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia. Ann Intern Med (1989) 111:807-812.
Campos RV et al. Differential expression of RNA transcripts encoding unqiue carboxy-terminal sequences of human parathyroid hormone-related peptide. Mol. Endocrinol. (1994) 8:1656-66.
Carron JA et al. PTHrP and the PTH/PTHrP receptor are co-expressed in human breast and colon tumors. Br J Cancer (1997) 76:1095-8.
CDC Press Release. Latest cancer incidence report shows prostate leading cancer among men, breast cancer leads for women. (2003) http://www.cdc.gov/cancer.
Christenson LJ et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA (2005) 294:681-690.
Deftos LJ. Prostate carcinoma. Production of bioactive factors. Second North American Symposium on Skeletal Complications of Malignancy (1999).
Diel IG et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl J Med (1998) 339:357-363.
Fahn HJ et al. The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma. J Urol (1991) 145:248-250.
Gallwitz WE et al. Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J. Clin. Invest. (2002) 110:1559-72.
Hall HI et al. Update on the incidence and mortality from melanoma in the United States. J. Am. Acad. Dermatol. (1999) 40:35-42.
Hanahan D et al. The hallmarks of cancer. Cell (2000) 100:57-70.
Harris JR et al. Diseases of the breast. Third edition.Philadelphia PA. Lippincot/Williams & Wilkins(2004) p. 971.
Iwamura M et al. Parathyroid hormone-related protein is an independent prognostic factor for renal cell carcinoma. Cancer (1999) 86:1028-1034.
Kao PC et al. Parathyroid hormone-related peptide in plasma of patients with hypercalcemia and malignancy lesions. Mayo Clin Proc (1990) 65:1399-1407.
Kissin MW et al. Parathyroid hormone related protein in breast cancer of widely varying prognostic. Eur J Surg Oncol (1993) 19:134-142.
Kremer R et al. Parathyroid hormone related peptide in hematologic malignancies. Am J Med (1996) 100:406-411.
Kumari R et al. Nuclear targeting of a midregion PTHrP fragment is necessary for stimulating growth in breast cancer cells. Int J Cancer (2006) 119:49-59.
Lauth M et al. Non-melanoma skin cancer: pathogenesis and mechanisms. Drug Discovery Today: Disease Mechanisms (2004) 1:267-72.
Liapis H et al. Expression of parathyroidlike protein in normal, proliferative and neoplastic human breast tissues. Am J Pathol (1993) 143:1169-78.
Rhim JS et al.Evidence for the multistep value of in vitro human epitheleial cell carcinogenesis. Cancer Res.(1990)50:5653.
Manenti G et al. A cancer modifier role for parathyroid hormone-related protein. Oncogene (2000) 19:5324-28.
Nishihara M et al. Clinicopathological implications of parathyroid hormone-related protein in human colorectal tumors. J Pathol (1999) 187:217-222.
Percherstorfer M et al. Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. J Clin Endocrinol Metab (1994) 76:1268-1270.
Ralston S et al. Hypercalcaemia and metastatic bone disease: is there a causal link? Lancet (1982) 2:903-905.
Rhim JS et al. Neoplastic transformations of human keratinocytes by polybrene-induced DNA-mediated transfer of an activated oncogene. Oncogene (1989) 4:1403-1409.
Roodman D. Mechanisms of bone metastasisN.Engl.J.Med. (2004) 350:1655-1664.
San Miguel JF et al. Prognostic factors and classification in multiple myeloma. Br J Cancer (1989) 59:113-118.
Sellers RS et al. Alternative splicing of parathyroid hormone-related protein mRNA: expression and stability. J Mol Endocrinol (2004) 33:227-241.
Shen X et al. Increased cell survival, migration invasion, and Akt expression overexpressing LoVo cancer cell lines. Regul. Pept. (2007) Jan 10; 17276526.
Shen X et al. PTH-related protein enhances LoVo colon cancer cell proliferation, adh integrin expression. Regul. Pept. (2005) 125:17-27.
Shen X et al. PTH-related protein enhances MCF-7 breast cancer cell adhesion, migr invasion via an intracrine pathway. Exp. Cell Res. (2004) 294:420-33.
Shen X et al. PTH-related protein modulates PC-3 prostate cancer cell adhesion an subunit profile. Mol. Cell Endocrinol. (2003) 199:165-77.
Shields JD et al. Lymphatic density and metastatic spread in human malignant melanoma. British Journal ofj Cancer (2004) 90:693-700.
Southby J et al. Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res (1990) 50:7710-7716.
Talon I et al. Antitumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo. Carcinogenesis (2006) 27:73-83.
Won C et al. Hypercalcemia in head and neck carcinoma. Incidence and prognosis. Cancer (1983) 52:2261-2263.
Yoshida A et al. Significance of the parathyroid hormone-related protein expression in breast carcinoma. Breast Cancer (2000) 7:215-20.
Grill V et al. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and in hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab (1991) 73:1309-1315.
Grone A et al. Cloning and sequencing of the 3′ region of the canine parathyroid hormone-related protein gene and analysis of alternative mRNA splicing in two canine carcinomas. Domest. Anim. Endocrinol. (2002) 22(3):169-77.
Guise TA et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast ca
Huang Dao Chao
Kremer Richard
Biochrom Pharma, Inc.
Canella Karen A
Schulman B. Aaron
Stites & Harbison PLLC
Wright Terry L.
LandOfFree
PTHrP, its isoforms and antagonist thereto in the diagnosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PTHrP, its isoforms and antagonist thereto in the diagnosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PTHrP, its isoforms and antagonist thereto in the diagnosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2714847